Over the past eight years, adriamycin, the outstanding representative of the anthracycline antibiotics, has demonstrated a remarkable activity against human and animal malignancies (1,2). Whereas adriamycin’s sibling, daunorubicin, has been impressive for remission induction in acute myelogenous and acute lymphocytic leukemias, adriamycin has a wider spectrum of activity and is useful against solid tumors. Clinical investigators in Europe, the Americas, Asia, and Africa find adriamycin has anticancer activity against soft tissue sarcomas, breast cancer, lung cancer, hepatomas, lymphomas, acute leukemias, etc. Against some malignancies, adriamycin has no useful pharmacologic activity. Complicating the usage of both adriamycin and daunorubicin are the toxic effects: myelosuppression, stomatitis, nausea, vomiting, alopecia, electrocardiographic changes, and a serious cumulative dosage related myocardiopathy.
KeywordsAcute Lymphocytic Leukemia Soft Tissue Sarcoma Acute Leukemia Amino Sugar Human Bile
Unable to display preview. Download preview PDF.
- 1.International Symposium on Adriamycin. Ed. S.K. Carter, A. DiMarco, M. Ghione, I.H. Krakoff, and G.. Mathe, Milan 1971, Springer-Verlag, Berlin, 1972.Google Scholar
- 2.Adriamycin New Drug Symposium. Ed. N.R. Bachur, R.S, Benjamin, and T.C. Hall, San Francisco 1975, Cancer Chemother. Rep., in press.Google Scholar
- 4.Waring, M: Progress in Molecular and Subcellular Biology. Ed. F.E. Hahn, Springer-Verlag, Berlin 2, 216 (1971).Google Scholar
- 5.Axelrod, M., Kaber, M., Bachur, N.R,: Unpublished observationsGoogle Scholar
- 11.Bachur, N.R., Takanashi, S., Arena, E.: Proc. XI Inter. Cancer Congress, Florence (1974).Google Scholar
- 13.Bachur, N.R. and Gee, M.: Fed. Proc. 31, 835 (1971).Google Scholar
- 14.Takanashi, S. and Bachur, N.R.: Proc. Amer. Assoc. Cancer Res. 15, 76 (1974).Google Scholar
- 15.Benjamin, R.S., Riggs, C.E., Jr., Serpick, A.A., and Bachur, N.R.: Clin. Res. 22, 483 (1974).Google Scholar